TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE The objective of this study was to evaluate the effects of photobiomodulation therapy (PBMT) on inflammatory indicators, i.e., inflammatory mediators (TNF-α and CINC-1), and pain characterized by hyperalgesia and B1 and B2 receptor activation at 6, 24, and 48 h after papain-induced osteoarthritis (OA) in rats. 27726041 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE TXYF improves PI-IBS symptoms by alleviating behavioral hyperalgesia and antidiarrhea, the underlying mechanism of which involves the inhibitory effects of TXYF on activating mucosal mast cells, downregulating tryptase and c-Fos expression, and reducing serum TNF-<i>α</i> and histamine levels. 28331524 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Neither of these inhibitors, however, affected tumor necrosis factor alpha, prostaglandin E2 or epinephrine hyperalgesia. 16472913 2006
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE Chronic exposure to tumor necrosis factor in vivo induces hyperalgesia, upregulates sodium channel gene expression and alters the cellular electrophysiology of dorsal root ganglion neurons. 28558976 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Thus, increased sensitization and up-regulation of TRPV1 constitutes a potential mechanism by which TNFalpha mediates inflammatory hyperalgesia and pain. 18582539 2008
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE In the present research, neuropathic pain induced Nrf2 and HO-1 expression in the microglial cells of the spinal cord; Nrf2 and HO-1 were necessary to alleviate the hyperalgesia of CCI-induced rats; NaHS mitigated the hyperalgesia and allodynia induced by the CCI operation; and NaHS mitigated the excessive release of the cytokines TNF-α, IL-1β, IL-6 and HMGB1 via the Nrf2/HO-1 pathway in the microglial cells of the spinal cord. 31325725 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Citronellol, a natural acyclic monoterpene, attenuates mechanical hyperalgesia response in mice: Evidence of the spinal cord lamina I inhibition. 26141506 2015
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE Curcumin significantly attenuated the diabetes-induced allodynia and hyperalgesia and reduced the expression of both TNF-α and TNF-α receptor 1. 23471081 2013
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Anti-inflammatory and analgesic effects of the sesquiterpene lactone budlein A in mice: inhibition of cytokine production-dependent mechanism. 17320857 2007
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. 10401557 1999
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human We propose endogenous TNFalpha as a key player in cancer-related heat hyperalgesia and nociceptor sensitization that generates TRPV1 upregulation and sensitization via TNFR2. 18463260 2008
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE In the present study, we evaluated RAc1 nano particle effects on hyperalgesia and liver hepcidin and serum IL-1β and TNF-α expression levels during acute and chronic phases of adjuvant-induced inflammation in male rats and compared its effects with Deferoxamine. 30776642 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE The CE and dichloromethane and hexane fractions reduced Cg-induced paw edema and hyperalgesia, LPS-induced fever, and plasma tumor necrosis factor-α (TNF-α) levels. 28332176 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype RGD The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. 16675114 2006
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype RGD Anti-TNF-alpha antibody reduces pain-behavioral changes induced by epidural application of nucleus pulposus in a rat model depending on the timing of administration. 17304130 2007
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE Immediately after hyperalgesia tests, blood samples were collected to analyze creatine kinase (CK) activity and the soleus muscle was removed for histological and tumor necrosis factor (TNF)-α immunohistological analyses. 30328526 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Hyperalgesia induced by both PLA(2)s was blocked by the histamine and serotonin receptor antagonists promethazine and methysergide, respectively, by the bradykinin B(2) receptor antagonist HOE 140 and by antibodies to tumor necrosis factor alfa (TNFalpha) and interleukin 1 (IL-1). 12727271 2003
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. 20383154 2010
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE The α7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-α in the hippocampus in mice. 31655281 2019
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE The aim of the current study was to investigate the effects of those two modalities on pain behavior and the expression of pro-inflammatory cytokines such as interleukin (IL)-1β and IL-6 and tumor necrosis factor-α (TNF-α) in the spinal cord and dorsal root ganglion (DRG) in a rat model of perioperative fentanyl induced hyperalgesia. 29657246 2018
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Post-treatment with S14080 dose-dependently antagonized the hyperalgesia induced by prostaglandin E2, bradykinin, dopamine and by the hyperalgesic cytokines reported to be released by carrageenin (tumour necrosis factor alpha, interleukin-1 and interleukin-8).3. 7881729 1995
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE Results revealed that increased hyperalgesia was concurrent with an increment of Iba1 (P < 0.001), TNF-α (P < 0.001), PTEN (P < 0.01), cleaved caspase-3 (P < 0.001), and a decrement of P.Akt (P < 0.01) during the acute phase of CFA-induced inflammation, while, at the same time as decreasing hyperalgesia during the chronic phase of study, Iba1 and TNF-α expression significantly decreased and PTEN, cleaved caspase-3, and P.Akt restored to baseline on day 0. 31388881 2020
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 Biomarker phenotype BEFREE Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freund's Adjuvant by a TRPV1-dependent mechanism in mice. 29132095 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia
0.600 AlteredExpression phenotype BEFREE TST led to significant development of cold allodynia; mechanical and heat hyperalgesia; dynamic mechanical allodynia; functional deficit in walking along with rise in the levels of TBARS, TNF-α, GSH and Nitrite. 24499201 2013